Previous studies have indicated that CSC in ovarian cancer are identified with high CD133 expression and increased aldehyde dehydrogenases (ALDH) activity, and presence of these cells predicts prognosis for reduced progression-free survival and poor patient outcome [8,9,10,11,12,13,14,15,16,17,18,19,20,21]. This evidence concerns the gene LDHA and ovarian cancer.